Lysine Biotech Logo

LYSINE BIOTECH PRIVATE LIMITED
 A Revolutionary CAR T-Cell Treatment with Global Potential
 CIN:U74999TN2018PTC122879
 

S.No1.PRODUCT 2nd generation of CAR T Cells Therapy Discovery stage and Early process development Preclinical Clinical trials
1LB101 Development of Commercial Novel huanti-CAR19T-CD27/41-BB-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety
50% Complete
2027
Lysine Biotech